Acute myeloid leukemia survival rates with Venetoclax

Acute myeloid leukemia (AML) is a heterologous myeloid neoplasm that reflects developmental arrest of hematopoietic precursor cells and occurs primarily at a median age of 68 years. BCL-2 is an apoptosis-regulating protein that is frequently overexpressed in AML. Venetoclax is an oral small molecule BCL-2 homology domain 3 (BH3) mimetic that inhibits BCL-2. However, venetoclax has limited efficacy as monotherapy for AML, in part due to primary and adaptive resistance.

In theVIALE-A trial, overall survival was 14.7 months for venetoclax plus azacitidine, which was significantly longer than 9.6 months for azacitidine alone. The use of venetoclax (and hypomethylating drugs) has become routine in the treatment of AML. There was no clear difference in response rates between azacitidine-venetoclax and decitabine-venetoclax in the first-line setting. In a retrospective study, the median response rate in the azacitidine-venetoclax group The overall survival was 12.3 months, which was significantly better than the 2.8 months in the decitabine-venetoclax group. In contrast, other retrospective analyzes showed that decitabine-venetoclax had a non-significant survival advantage compared with azacitidine-venetoclax.

The original drug of Venacla is already on the market in China, and can be found in the Category B medical insurance directory. The specification is 100mg*14 tablets and the price per box may be around RMB 5,000. The Turkish version of Venaclaoriginal drug, specifications100mg*112 tablets, sold overseas, costs around RMB 10,000 per box (the price may fluctuate due to exchange rates), which is even more expensive. Cheaper generic drugs are also sold overseas, and their pharmaceutical ingredients are basically the same as those of the original drugs. The price of a box of 100mg*120 tablets produced by a Bangladeshi pharmaceutical factory is around RMB 4,000 (prices may fluctuate due to exchange rates).